About Walvax
Walvax is a company based in Kunming (China) founded in 2001. The company has 1,930 employees as of December 31, 2024. Walvax operates in a competitive market with competitors including Serum Institute of India, Vaxcyte, HOOKIPA Pharma, Vir Biotechnology and Biological E, among others.
- Headquarter Kunming, China
- Employees 1930 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Walvax Biotechnology Co., Ltd. Class A
-
Annual Revenue
$383.59 M (USD)-31.34as on Dec 31, 2024
-
Net Profit
$19.48 M (USD)-66.1as on Dec 31, 2024
-
EBITDA
$66.9 M (USD)-50.53as on Dec 31, 2024
-
Latest Funding Round
$72.8 M (USD), Post-IPO
Aug 10, 2014
-
Investors
Not available
-
Employee Count
1930
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Walvax
Walvax is a publicly listed company on the SZSE with ticker symbol 300142 in China, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Funding Insights of Walvax
Investments & Acquisitions by Walvax
Investment portfolio details for Walvax
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Walvax
Detailed financials for Walvax
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Walvax Comparisons
Peer comparison for Walvax
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Walvax
Walvax operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Serum Institute of India, Vaxcyte, HOOKIPA Pharma, Vir Biotechnology and Biological E, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Vaccines and immuno-biological drugs for infectious diseases are manufactured.
|
|
| Locked | Locked | Locked |
Vaccines for infectious diseases are developed using cell-free protein synthesis.
|
|
| Locked | Locked | Locked |
Developer of immunotherapies for the treatment of infectious diseases and cancer
|
|
| Locked | Locked | Locked |
Developer of therapeutics for the treatment of infectious diseases
|
|
| Locked | Locked | Locked |
Vaccines and therapeutics for multiple diseases are developed and marketed.
|
|
| Locked | Locked | Locked |
Gene therapy platform is developed for chronic disease treatments.
|
Detailed competitors of Walvax
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Walvax
Complete news archive for Walvax
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Walvax
Walvax was founded in 2001 and raised its 1st funding round 13 years after it was founded.
Walvax is headquartered in Kunming, China. It is registered at Kunming, Yunnan, China.
As of Dec 31, 2024, the latest employee count at Walvax is 1,930.
Annual revenue of Walvax is $383.59M as on Dec 31, 2024.
Walvax was founded in 2001 in Kunming, China, as a vaccine manufacturer focused on the biopharmaceutical sector. Specialization is placed on developing and producing vaccines against meningitis and influenza. An in-house RD center is operated to support innovation. The company was listed publicly in November 2010, enabling expanded operations within the Chinese market and beyond.
Walvax's top competitors include Vaxcyte, HOOKIPA Pharma and Serum Institute of India.
Yes, Walvax is publicly traded on SZSE under the ticker symbol 300142.
The ticker symbol of Walvax is 300142 on SZSE.